Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Clinical trial NCT05111626 · TERMINATED

Trial details

NCT number: NCT05111626
Sponsor: Amgen
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric Cancer Gastroesophageal Junction Adenocarcinoma

Start date: 2022-03-14
Primary completion: 2025-10-14
Enrollment: 515

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.